Redwing-
The 68Ga PSMA scan I had at UCSF does not have a minimum PSA for biochemical recurrence, only a doubling time under 12 months.
Not sure yet if insurance is covering this?
Inclusion Criteria:
Known prostate cancer with a clinical concern for the presence of metastatic disease as delineated below:
Treatment naïve patients with one of the following risk factors: CAPRA (Cancer of the Prostate Risk Assessment) score ≥ 5, PSA ≥ 15 ng/mL and/or Gleason score ≥ 4+4.
Patients with biochemical recurrence after prostatectomy or radiation therapy with a PSA doubling time less than 12 months.
i. These patients may have received androgen deprivation therapy prior to imaging.
Patients with castrate resistant prostate cancer with progressive disease as defined by PCWG2 criteria (27).
i. Patients with castrate resistant prostate cancer can be either on treatment or off treatment
Age > 18.
Karnofsky performance status of > 50 (or ECOG/WHO equivalent).
Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria:
Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET scanner due to BMI.
Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.).
Inability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.).
[url]